Klee Justin B.'s Form 4 filing
Amylyx Pharmaceuticals, Inc. (AMLX) · filed Jan 20, 2026
- Accession no.
- 0001193125-26-017056
- Filed
- Jan 20, 2026
- Trade date
- Jan 15-16, 2026
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.88M. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Klee Justin B.CIK 0001898314 | Director, Officer (Co-Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 15, 2026 | Common Stock | MOption exerciseAcquired | +197,153 | $7.57 | +$1,492,448.21 | 3,514,739 | Direct | |
| Jan 15, 2026 | Common Stock | SSaleDisposed | −136,193 | $13.58F2 | −$1,849,500.94 | 3,378,546 | Direct | |
| Jan 16, 2026 | Common Stock | MOption exerciseAcquired | +2,847 | $7.57 | +$21,551.79 | 3,381,393 | Direct | |
| Jan 16, 2026 | Common Stock | SSaleDisposed | −1,995 | $13.89F3 | −$27,710.55 | 3,379,398 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 15, 2026 | Common Stock | MOption exerciseDisposed | −197,153 | $0.00 | $0 | 2,847 | Direct | |
| Jan 16, 2026 | Common Stock | MOption exerciseDisposed | −2,847 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.26 to $13.77. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.83 to $13.91. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.